FDA approves maintenance olaparib for BRCA-mutated metastatic pancreatic cancer

The FDA approved olaparib as maintenance treatment for adults with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic cancer, according to a press release from the drug’s manufacturer.The approval of olaparib (Lynparza; AstraZeneca, Merck) applies to patients whose disease did not progress after at least 16 weeks of first-line platinum chemotherapy.“Patients with advanced pancreatic cancer historically have faced poor outcomes due to the aggressive nature of the disease and limited treatment advances over the last few decades,” Dave Fredrickson,Read More

Share on facebook
Share on twitter
Share on linkedin